Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
Status:
Completed
Trial end date:
2021-02-15
Target enrollment:
Participant gender:
Summary
MIN-101C07 is a multicenter, multinational, randomized, double-blind, placebo-controlled,
parallel-group study to evaluate the efficacy and safety of roluperidone in adult
schizophrenia patients.The primary objective is to evaluate the efficacy of 2 fixed doses of
roluperidone compared to placebo in improving the negative symptoms of schizophrenia over 12
weeks of double-blind treatment as measured by the change in Positive and Negative Syndrome
Scale (PANSS) Marder negative symptoms factor score (NSFS) over 12 weeks.